COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
SAGE Open Med Case Rep
; 11: 2050313X221148548, 2023.
Article
in English
| MEDLINE | ID: covidwho-2227919
ABSTRACT
Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
Language:
English
Journal:
SAGE Open Med Case Rep
Year:
2023
Document Type:
Article
Affiliation country:
2050313X221148548
Similar
MEDLINE
...
LILACS
LIS